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BACKGROUND: Although it has long been recognized that smooth muscle 
Na/K ATPase modulates vascular tone and blood pressure (BP), the role of its 
accessory protein phospholemman has not been characterized. The aim of 
this study was to test the hypothesis that phospholemman phosphorylation 
regulates vascular tone in vitro and that this mechanism plays an important 
role in modulation of vascular function and BP in experimental models in vivo 
and in humans.
METHODS: In mouse studies, phospholemman knock-in mice (PLM3SA; 
phospholemman [FXYD1] in which the 3 phosphorylation sites on serines 63, 
68, and 69 are mutated to alanines), in which phospholemman is rendered 
unphosphorylatable, were used to assess the role of phospholemman 
phosphorylation in vitro in aortic and mesenteric vessels using wire 
myography and membrane potential measurements. In vivo BP and regional 
blood flow were assessed using Doppler flow and telemetry in young 
(14–16 weeks) and old (57–60 weeks) wild-type and transgenic mice. In 
human studies, we searched human genomic databases for mutations in 
phospholemman in the region of the phosphorylation sites and performed 
analyses within 2 human data cohorts (UK Biobank and GoDARTS [Genetics 
of Diabetes Audit and Research in Tayside]) to assess the impact of an 
identified single nucleotide polymorphism on BP. This single nucleotide 
polymorphism was expressed in human embryonic kidney cells, and its effect 
on phospholemman phosphorylation was determined using Western blotting.
RESULTS: Phospholemman phosphorylation at Ser63 and Ser68 limited 
vascular constriction in response to phenylephrine. This effect was blocked by 
ouabain. Prevention of phospholemman phosphorylation in the PLM3SA mouse 
profoundly enhanced vascular responses to phenylephrine both in vitro and in 
vivo. In aging wild-type mice, phospholemman was hypophosphorylated, and 
this correlated with the development of aging-induced essential hypertension. 
In humans, we identified a nonsynonymous coding variant, single nucleotide 
polymorphism rs61753924, which causes the substitution R70C in 
phospholemman. In human embryonic kidney cells, the R70C mutation 
prevented phospholemman phosphorylation at Ser68. This variant’s rare allele 
is significantly associated with increased BP in middle-aged men.
CONCLUSIONS: These studies demonstrate the importance of 
phospholemman phosphorylation in the regulation of vascular tone and BP 
and suggest a novel mechanism, and therapeutic target, for aging-induced 
essential hypertension in humans.
Phospholemman Phosphorylation 
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The Na/K ATPase is ubiquitously expressed and maintains the Na and K transmembrane gradi-ents essential for a plethora of cell functions in-
cluding electric excitability, secondary active transport, 
and cell signaling.1–3
In vascular smooth muscle cells, the Na/K ATPase 
(specifically the α2 isoform) plays an important role in 
modulating vascular smooth muscle cell tone and blood 
pressure (BP).1,2,4–7 The hypertensive effects of Na/K 
pump inhibition with both exogenous and endogenous 
cardiotonic steroids have long been recognized.8–10 
Agents that stimulate the pump are hypotensive, where-
as agents that inhibit the pump (and specifically the 
α2 subunit in vascular smooth muscle) are hyperten-
sive.8,9,11 Endogenous cardiotonic steroids, for example, 
play a role in setting BP,12 and exogenous ouabain com-
pletely blocks classical acetylcholine-induced nitric oxide 
(NO)–mediated vasodilation13 and substantially blocks 
reactive hyperemia14—suggesting that Na/K ATPase ac-
tivity not only influences vascular contractility but also is 
central to the action of endogenous vasodilators.4,15–19
Despite overwhelming evidence for a role of the 
Na/K ATPase in regulation of smooth muscle tone and 
BP, surprisingly little is known about the role of phos-
pholemman, the muscle-specific regulator of Na/K 
ATPase, in modulating BP, and even less is known about 
its possible contribution to hypertension. Phospholem-
man (FXYD1) is a member of the FXYD family of Na/K 
ATPase modulatory proteins and in cardiac muscle links 
cellular signaling pathways (specifically protein kinase 
C [PKC] and protein kinase A [PKA]) to Na/K pump acti-
vation.20 In the heart, phosphorylation of phospholem-
man disinhibits the Na/K ATPase by lowering its affinity 
for Na (Km) and by increasing its maximal activity (Vmax) 
and hence increases Na efflux in response to hormonal 
stimulation and heart rate elevation.21–23
Although phospholemman is expressed in vascular 
smooth muscle, its role in regulating Na/K ATPase in 
this tissue has not been established, and the limited 
literature is incomplete and contradictory.24–26 Thus, al-
though there is limited evidence that phospholemman 
may regulate Na/K ATPase in vascular smooth muscle, 
the physiological relevance of this is far from certain, 
and its role in the control of BP has yet to be demon-
strated. The primary aim of this study was, therefore, to 
test the hypothesis that phospholemman phosphoryla-
tion regulates vascular tone in vitro and this mechanism 
plays an important role in modulation of vascular func-
tion and BP in vivo.
METHODS
An expanded Methods section is available in the Data 
Supplement. The authors declare that all supporting data 
are available within the article and the Data Supplement or 
are available from the corresponding author on reasonable 
request. Access to source patient datasets is available to suit-
ably qualified researchers through UK Biobank (UKBB) (https://
www.ukbiobank.ac.uk) and GoDARTS (Genetics of Diabetes 
Audit and Research in Tayside; https://godarts.org).
Animals and PLM3SA Mice
All experiments were performed in accordance with the 
Guidance on the Operation of Animals (Scientific Procedures) 
Act, 1986 (UK) and the Directive of the European Parliament 
(2010/63/EU) and received approval by the King’s College 
London Ethics Review Board. Male PLM3SA (phospholemman 
[FXYD1] in which the 3 phosphorylation sites on serines 63, 
68, and 69 are mutated to alanines) knock-in mice or their 
wild-type (WT) littermates (13–16 weeks of age [young] or 
56–60 weeks of age [old]), were used in the majority of stud-
ies. A small number of studies used male Wistar rats (250 g; 
Charles River, UK).
Myography
Vascular rings were isolated from thoracic aortae of WT and 
PLM3SA mice, or rats, mounted in a tension myograph (Danish 
Myo Technology) and optimally stretched. Endothelial integ-
rity was then tested (with acetylcholine) and concentration-
response curves to phenylephrine and the thromboxane A2 
mimetic U46619 constructed in the presence or absence of 
Clinical Perspective
What Is New?
• Despite many previous studies implicating smooth 
muscle Na/K ATPase and endogenous cardiotonic 
steroids in hypertension, this is the first study dem-
onstrating a role for its principle regulatory acces-
sory protein phospholemman (PLM).
• Phosphorylation of PLM profoundly influences vas-
cular tone and blood pressure regulation in mice, 
and its hypophosphorylation is associated with 
aging-induced essential hypertension.
• In humans, a single nucleotide polymorphism was 
identified in PLM exon 10 that results in an R70C 
mutation that in vitro leads to PLM hypophosphor-
ylation and, in 2 human cohorts (UK Biobank and 
GoDARTS [Genetics of Diabetes Audit and Research 
in Tayside]), is associated with a significant eleva-
tion of blood pressure in middle-aged men.
What Are the Clinical Implications?
• Interventions that prevent PLM dephosphorylation 
and Na/K ATPase downregulation may provide new 
therapeutic approaches to treatment of essential 
hypertension.
• Existing interventions that prevent downregula-
tion of signaling pathways that terminate in PLM 
phosphorylation (for example, β-blockers) may in 
part exert their beneficial antihypertensive effect 
through this mechanism.
• The age- and sex-dependence of these observa-
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ouabain. Changes in isometric tension were sampled and 
recorded at 100 Hz using a PowerLab and LabChart soft-
ware (AD Instruments, New Zealand).
In Vivo Hemodynamic Assessment in Mice
Central arterial BP was measured in anesthetized mice via a 
pressure-tipped catheter (1.2F, Transonic) inserted retrogradely 
into the ascending aorta via the right common carotid artery. 
The left jugular vein was cannulated for phenylephrine infusion. 
Surface ECG was continuously recorded. Augmentation index 
(AI) was calculated as previously described (see also, Figure V in 
the Data Supplement).27 In separate experiments, noninvasive 
laser Doppler imaging (MoorLDI2 model, Moor Instruments Inc, 
Wilmington) was used to assess hind-limb blood flow. Continuous 
hemodynamic measurements in conscious mice were performed 
by telemetry as described previously.28 Cardiac structure and func-
tion were assessed by 2-dimensional echocardiography.29
Immunoblotting
Thoracic aortae or mesenteric vessels were harvested from 
PLM3SA and WT mice, cleaned of fat and connective tissue, 
cut into 3 or 4 pieces, and incubated at 37oC in gassed Krebs 
solution or Krebs plus phenylephrine (10 µmol/L), U46619 (1 
µmol/L) or spermine NONOate (spNONO) (100 µmol/L). The 
tissue was snap-frozen and stored at –80°C. Tissue homog-
enates (4% wt/vol) were size-fractionated on SDS-PAGE gels 
(10% to 15%) and processed for Western blotting as pre-
viously described.29 α-Smooth muscle actin was used as a 
loading control. Signals from PLM3SA samples or treated WT 
samples were normalized to signals from control WT samples 
on the same gels or, for phospholemman phosphorylation, 
to total phospholemman. Details of antibodies, procedures, 
and quantification can be found in the Data Supplement.
Membrane Potential Measurements
Membrane potential was measured in 2-mm segments of 
third-order mesenteric arteries mounted in a Mulvany-Halpern 
wire myograph (model 400A, Danish Myo Technology, 
Denmark) using sharp glass microelectrodes backfilled with 2 
mol/L KCl (tip resistances ≈100 MΩ). Tension was simultane-
ously recorded.30,31
Genomic and Phenotypic Screening in 
Patient Populations
We searched human genomic databases for mutations in 
phospholemman in the region of the phosphorylation sites. 
rs61753924 is a single nucleotide polymorphism (SNP) at 
35 633 635 bp position (build hg19/37) on chromosome 19, 
in phospholemman exon 10, a C to T transition in posi-
tion 1 of the codon encoding arginine 70 that generates 
a nonsynonymous variant with the amino acid substitution 
R70C. To assess the impact of this SNP on BP, we analyzed 
this SNP within 2 different human cohorts: UKBB32 and 
GoDARTS.33,34 Details of the cohorts and the analysis can be 
found in the Data Supplement.
The human database analysis was been conducted using 
the UKBB Resource under application No. 236. The genetic 
and phenotypic patient cohort data are available on applica-
tion to UKBB (https://www.ukbiobank.ac.uk) and GoDARTS 
(https://godarts.org). The UKBB study has approval from the 
North West Multi-Center Research Ethics Committee. Any 
participants from UKBB or GoDARTS who withdrew consent 
have been removed from our analysis.
Statistics
Data are shown as mean ± SEM. Details of the analyses used 
can be found in the Data Supplement.
RESULTS
Prevention of Phospholemman 
Phosphorylation Potentiates 
Phenylephrine-Induced Vasoconstriction
Figure 1A shows the dose-dependent constriction of iso-
lated aortic rings to phenylephrine was potentiated in tis-
sues isolated from PLM3SA mice. The response of PLM3SA 
tissue was unaffected by ouabain, but inhibition of Na/K 
ATPase in WT tissue rendered the WT hyperresponsive to 
phenylephrine and similar to PLM3SA (Figure 2B).
Although phenylephrine-induced constriction was 
profoundly different between genotypes, and this dif-
ference was Na/K ATPase–dependent, no differences 
were seen between genotypes in response to U46619 
(Figure 1C). Although U46619 interestingly also induced 
phospholemman phosphorylation at Ser63 and Ser68 
(Figure 1F), this did not limit maximal constriction in WT 
aortae, suggesting that, unlike phenylephrine-induced 
constriction, high concentrations of U46619 (0.1–30 
µmol/L) mediate their constrictor effects via cellular 
mechanisms that are largely unaffected by phospholem-
man phosphorylation and Na/K ATPase activity. This is 
unsurprising because at these concentrations, U46619 
has been shown to potently inhibit the Na/K ATPase.35
In parallel experiments, Western blot analysis (Fig-
ure  1D–1F) showed that phenylephrine (10 µmol/L) 
and U46619 (1 µmol/L) induced substantial phospho-
lemman phosphorylation at Ser63 (phenylephrine) and 
Ser63 and Ser68 (U46619) in WT aortae. Expression of 
phospholemman, and both α1 and α2 subunits of the 
Na/K ATPase in aortic smooth muscle, was unaffected 
by genotype (Figure I in the Data Supplement).
A similar disparity between the role of Na/K ATPase in 
mediating the constrictor effects of phenylephrine and 
U46619 was also seen in rat aorta (Figure II in the Data 
Supplement). At concentrations of U46619 <30 nmol/L, 
there is a small ouabain-sensitive component (Figure IIB 
in the Data Supplement). Interestingly, U46619 induces 
phospholemman phosphorylation (Figure  1D and 1F) 
which, because of its concomitant Na/K ATPase inhi-
bition, is largely without effect. This phospholemman 
phosphorylation is likely to reflect our previous observa-
tion that interventions raising cytosolic Ca will increase 
phospholemman phosphorylation by activating Ca-de-
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of ouabain on constriction in rat aorta at submaximal 
U46619 concentrations (ie, <30 nmol/L), where the 
Na/K pump may still not be fully inhibited by U46619.
On the basis of these experiments, we conclude that 
α1 adrenoceptor stimulation activates signaling pathways 
leading to phosphorylation of phospholemman at Ser63 
(presumably through a PKC-dependent mechanism)36 and 
Na/K ATPase activation. In WT tissue, this exerts a oua-
bain-sensitive “relaxing” effect that limits the overall con-
strictor effect of phenylephrine. When phospholemman 
phosphorylation is prevented in PLM3SA tissue, or when 
the Na/K ATPase is inhibited by ouabain (or U46619), this 
“relaxing” effect is lost, and constriction is potentiated.
Phospholemman-Dependent Limitation of 
Phenylephrine-Induced Constriction in WT Aortae 
Is Partially Blocked by L-NG-Nitro Arginine 
Methyl Ester
Previous studies have shown that endothelially de-
rived factors modulate vascular responses to α1-
adrenergic agonists via Na/K ATPase–dependent 
mechanisms.4,15–18,37 Furthermore, we have previously 
demonstrated that NO exerts phospholemman-de-
pendent modulation of Na/K pump in cardiac tissue.38 
We therefore hypothesized that at least part of the 
mechanism limiting phenylephrine-induced constric-
tion in WT aortae may be NO-dependent. Figure IIIA 
in the Data Supplement shows the enhanced response 
of PLM3SA tissues to phenylephrine (cf WT; Figure 1A). 
Subsequent nitric oxide synthase (NOS) inhibition 
with L-NG-Nitro Arginine Methyl Ester (L-NAME; 300 
μmol/L) increased the dose-dependent contractile re-
sponse to phenylephrine in both genotypes, but the 
relative potentiation was more profound in WT mice 
than PLM3SA (Figure III in the Data Supplement). As a 
result of this potentiation, the difference in contrac-
tile responses between genotypes after NOS inhibition 
was substantially reduced but still statistically signifi-
cant (Figure IIIB in the Data Supplement).
These data suggest that in WT aortae, the ouabain-
sensitive mechanism limiting phenylephrine-induced 
constriction has 2 components: a NOS-dependent com-
ponent (blocked by L-NAME) and a NOS-independent 
component (which persists in L-NAME).
A B C
D E F
Figure 1. Phospholemman (PLM) phosphorylation limits phenylephrine-induced vasoconstriction in wild-type (WT) isolated mouse aortic rings in a 
ouabain-sensitive manner.
Mutation of PLM to prevent phosphorylation (3SA) enhances constriction. Constriction in response to the thromboxane A2 mimetic U46619, which also increases 
PLM phosphorylation, was unaffected by genotype. A, Mutation of PLM phosphorylation sites to prevent phosphorylation markedly enhanced vasoconstriction 
(n=6 [WT] and n=5 [3SA], #P<0.001, 2-way ANOVA for comparison of maximal responses). B, The limitation of vasoconstriction in WT aortae was completely 
blocked by pretreatment with ouabain (300 μmol/L; n=5 per group). C, Contractile response to the thromboxane A2 mimetic U46619 was unaffected by genotype 
(n=6 [WT] and n=7 [3SA]). D through F, In WT aortae, both phenylephrine (10 µmol/L) and U46619 (1 µmol/L) markedly increased PLM phosphorylation (n=6 per 
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Aortic Rings From WT Mice Are More Sensitive to 
an NO Donor
To further investigate the role of phospholemman 
phosphorylation in NO-dependent regulation of the 
Na/K pump, in the next series of experiments, we 
compared NO-dependent relaxation of aortic rings 
from both genotypes preconstricted with a low con-




Figure 2. In vivo measurements of aortic stiffness as assessed by augmentation index, and peripheral blood flow measured in anesthetized wild-
type (WT) and PLM3SA (3SA) mice in response to phenylephrine.
Phenylephrine (PE) was infused as a bolus injection via a left jugular vein catheter at the doses indicated. A, Aortic pressure measurements were made via a pressure-
tipped catheter (1.2F, Transonic) introduced into the ascending thoracic aorta via the right carotid artery. Augmentation index was measured as the percentage in-
crease in aortic pressure from the first inflection in the aortic pressure trace to the subsequent peak pressure (n=5 for both groups). B through D, In separate experi-
ments, peripheral blood flow was measured in the hind limb by laser Doppler in response to PE bolus infusion (n=5 [3SA] and n=6 [WT]). In B and C, comparisons 
were made using 2-way ANOVA with Bonferroni correction and #P<0.001 for effect of both genotype and PE concentration and specifically *P<0.05, ***P<0.001. 
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used in these experiments was 40 nmol/L because at 
this concentration there is still an ouabain-sensitive 
modulation of constriction (Figure  2B), whereas at 
higher concentrations, U46619 is reported to directly 
inhibit Na/K ATPase.35 Initial tension after treatment 
with U46619 was the same across genotypes, but 
spNONO-induced relaxation curves were left-shifted 
in aortic rings from WT mice, which reflects higher 
sensitivity of this genotype to NO (Figure IVA in the 
Data Supplement). Interestingly, pretreatment with 
ouabain (100 μmol/L) profoundly limited the maximal 
relaxation response to NO and completely abolished 
the shift in the Km for spNONO between genotypes 
(Figure IVB in the Data Supplement). These results 
demonstrate that (1) phospholemman-dependent 
Na/K pump activation is one of the mechanisms in-
volved in NO-dependent relaxation, (2) Na pump–
independent mechanisms are not different between 
genotypes, and (3) phospholemman phosphorylation 
facilitates NO-dependent relaxation of WT aortic rings. 
Further evidence for a role of phospholemman phos-
phorylation in NO-dependent relaxation was seen in 
immunoblot experiments. Treatment of isolated aortic 
segments from WT mice with spNONO (100 µmol/L) 
time-dependently increased phospholemman phos-
phorylation (Figure IVC–IVE in the Data Supplement).
Thus, these in vitro experiments show that phospho-
lemman phosphorylation and consequent Na/K ATPase 
activation both limit the contractile response to phen-
ylephrine and enhance NO-dependent relaxation. Our 
next aim was to test whether such in vitro observations 
made in aortic rings are also seen in vivo and to estab-
lish whether phospholemman phosphorylation there-
fore plays a role in regulating vascular tone and BP.
Vascular Constriction in Response to 
Phenylephrine Is Profoundly Enhanced in PLM3SA 
Mice In Vivo
We measured AI in anesthetized mice as an index of 
aortic stiffness/tone in vivo (Figure  2A). AI was mea-
sured in WT and PLM3SA mice at baseline and during 
phenylephrine infusion (IV 10–300 μg/kg). Baseline AI 
was not different between genotypes, but phenyleph-
rine treatment induced a dose-dependent elevation of 
AI in both genotypes. Furthermore, the increase in AI in 
response to phenylephrine was significantly enhanced 
in PLM3SA compared with WT mice (Figure 2A).
Phenylephrine-induced differences in AI could 
reflect differences in cardiac contractility, vascular 
stiffness, or both. To determine the contribution of 
any genotype-specific cardiac response to phenyl-
ephrine infusion, in separate experiments, isolated 
hearts were treated with phenylephrine (Figure VC 
in the Data Supplement). Phenylephrine modestly in-
creased contractility of both WT and PLM3SA hearts 
to an identical extent. We conclude that the greater 
phenylephrine-induced elevation of AI in PLM3SA mice 
reflects enhanced vascular contractility in this model.
To establish whether this enhanced vasocontrac-
tile response to phenylephrine in the PLM3SA mice 
is unique to aorta (or is a general feature of other 
vascular beds), blood flow in response to phenyleph-
rine bolus injection was measured in the hind limb. 
Noninvasive laser Doppler hind-limb imaging in the 
2 genotypes showed no differences in blood flow 
under baseline conditions (Figure 2B–2D). However, 
acute bolus phenylephrine infusion (IV 30–300 μg/
kg) induced a more profound reduction of blood flow 
in PLM3SA mice than in WT littermates (Figure 2B–2D) 
at all phenylephrine concentrations. These data are 
consistent with the observation in Figure  2A of an 
enhanced constrictor response in aorta (AI) and aug-
mented vascular contractility in phospholemman 
mutant mice in response to phenylephrine treatment 
in vivo.
BP Changes in PLM3SA Mice: Changes in 
Baroreceptor Gain and Autonomic Function
Baseline BP was the same in conscious and anes-
thetized mice of both genotypes (Figure 3A, Figure 
VIA in the Data Supplement). Given the profoundly 
enhanced constrictor response of PLM3SA mouse to 
phenylephrine both in vitro and in vivo, surprisingly, 
phenylephrine infusion (IV 10–300 μg/kg) induced 
identical dose-dependent pressor responses in WT 
and PLM3SA mice (Figure 3A). This appears to be ex-
plained by differences between genotypes in their 
baroreceptor function. Figure  3B shows that the 
pressure-induced bradycardia was far more profound 
in PLM3SA than WT mice. Baroreceptor sensitivity can 
be estimated by plotting the change in heart rate (RR 
interval) as a function of change in BP (Figure 3C). 
From this figure, it is clear that the baroreceptor re-
flex gain, as measured by the slope of this relation-
ship, is almost 3 times higher in PLM3SA (1.42±0.11 
ms·mm Hg–1) than WT mice (0.5±0.07 ms·mm Hg–1). 
This baroreceptor adaptation clearly allows the PLM3SA 
mouse to maintain normal BPs at rest, and over a 
range of pressor interventions, despite hypercontrac-
tile vascular smooth muscle. Figure VIB and VIC in 
the Data Supplement also shows that these changes 
in baroreceptor reflex gain allow the PLM3SA mice to 
maintain comparable changes in systolic BP in re-
sponse to acute environmental stress by limiting heart 
rate changes. Further evidence for autonomic adap-
tation in these mice is shown in the heart rate vari-
ability analysis in Figure 3D and autonomic balance 
(Figure VID in the Data Supplement). PLM3SA mice 
show significantly reduced low- to high-frequency 
ratio (Figure 3D) consistent with a chronic adaptive 
reduced sympathetic dominance and altered auto-
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Membrane Potential Measurements in 
Mesenteric Vessels: Role of Electrogenic 
Na/K Pump Activation?
The high-input impedance of vascular smooth muscle 
means that small changes in electrogenic Na/K pump 
activity can exert large effects on membrane potential 
(Em) and hence constriction. We therefore hypothesized 
that the ouabain-sensitive differences in response to 
phenylephrine are mediated by changes in Em. Fig-
ure 4A shows that at rest, Em of WT mesenteric resis-
tance vessels was –55±1.0 mV. Of this, about –8 mV 
can be attributed to the outward current carried by 
Na/K ATPase because ouabain, in WT vessels, reduces 
Em to –47±0.8 mV. In the PLM
3SA mouse, Em was consid-
erably depolarized at rest (–50±0.5 mV), and Em was no 
longer sensitive to ouabain—suggesting that, at rest, in 
the PLM3SA mouse, the contribution of the electrogenic 
Na/K ATPase to membrane potential is minimal. In WT 
mesentery (as in aorta, Figure  1D and 1E), phospho-
lemman was basally phosphorylated at Ser63 (Figure 
VII in the Data Supplement). However, unlike in aorta, 
phenylephrine did not induce further phospholemman 
phosphorylation at either Ser63 or Ser68 (Figure VII in 
the Data Supplement). The ability of phenylephrine to 
induce phospholemman phosphorylation in aortic but 
not mesenteric vessels suggests that although the Na/K 
ATPase and phospholemman exert tonic effects on 
A B
C D
Figure 3.  In vivo measurements of mean arterial pressure (MAP), heart rate, baroreceptor reflex gain, and autonomic function in anesthetized wild-
type (WT) and PLM3SA (3SA) mice in response to phenylephrine.
Phenylephrine (PE) was infused as a bolus injection via a jugular vein catheter at the doses indicated. A, MAP measurements were made as described in Figure 2, 
and heart rate (B) was a calculated from the pressure trace. Baroreceptor reflex gain (BRG) was estimated by plotting the change in beat-beat interval (ΔRR) as 
a function of change in MAP (ΔMAP) in response PE infusion (C) with BRG estimated as the slope of this relationship (*P<0.05). The low/high frequency (LF/HF) 
component (sympathetic dominance) of heart rate variability measured in conscious telemetered mice under control conditions is shown in D. A through C, n= 5  
per group. D, n=11 per group. B, comparisons were made using 2-way ANOVA with Bonferroni correction and #P<0.001 for effect of both genotype and PE 
concentration and specifically *P<0.05. Difference in D was tested using an unpaired t test, **P<0.005. PLM3SA indicates phospholemman (FXYD1) in which the 3 
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vascular tone and membrane potential, the ability for 
this to be modulated by phenylephrine may vary in dif-
ferent vascular beds. The inability of phenylephrine to 
induce phospholemman phosphorylation also explains 
the similar constrictor responses to phenylephrine seen 
in WT and PLM3SA mesenteric vessels (Figure VIII in the 
Data Supplement).
Role of Phospholemman 
Dephosphorylation in Aging-Induced 
Essential Hypertension in Mice
Having demonstrated the importance of phospho-
lemman phosphorylation in the regulation of vascular 
smooth muscle tone and BP in young mice, we inves-
tigated whether changes in phospholemman phos-
phorylation are associated with aging-induced essential 
hypertension. Figure 5A shows the diurnal variation in 
mean arterial pressure in young mice (14–16 weeks of 
age) and old hypertensive mice (57–60 weeks of age). 
In aortae from young mice, phospholemman was sig-
nificantly basally phosphorylated at all 3 serine residues 
(Figure 5D and 5E). However, in old hypertensive mice, 
phospholemman was substantially hypophosphorylat-
ed and overexpressed (Figure 5D and 5E). There were 
no significant differences in α1 or α2 Na/K ATPase sub-
unit expression with age (Figure IXA in the Data Supple-
ment), but the increase in phospholemman expression 
resulted in a significant relative excess of unphosphor-
ylated phospholemman in old mice (Figure IXB in the 
Data Supplement).
BP in young and old WT and PLM3SA mice is shown in 
Figure 5B and 5C. Whereas WT mice show substantial ag-
ing-induced hypertension during both the day and night, 
PLM3SA mice are completely protected against hyperten-
sion at rest (day) and substantially protected against hy-
pertension during activity (night). In old WT mice, average 
mean arterial pressure at rest (day) was +13 mm Hg higher 
than in young mice, and this hypertension was completely 
prevented in PLM3SA mice. During activity (night), old WT 
mice showed a substantial aging-induced hypertension 
(+18 mm Hg) that was substantially abrogated in the PLM-
3SA genotype (+10 mm Hg). The heart rate variability differ-
ences seen in young mice (Figure 3D) were still present in 
aged mice (Figure X in the Data Supplement). PLM3SA mice 
were protected not only against aging-induced hyperten-
sion but also against aging-induced cardiac dysfunction 
(Figure 5F, Figure XI in the Data Supplement).
Homologous Variant in a Human 
Population Influences BP
We identified an SNP in phospholemman that generates 
an R70C amino acid substitution in phospholemman. 
We hypothesized that R70C is unlikely to influence 
phosphorylation at phospholemman Ser68 by protein 
kinase A (consensus motif RRXS/T). PKC isoforms gen-
erally require positive charges in positions +3, +2, –2, 
and –3 (consensus RRXS/TXRR),39 so we hypothesized 
that phosphorylation by PKC at Ser68 (but not Ser63 
and Thr69) may be perturbed (Figure 6A). We also in-
vestigated the possibility that mutation R70C destroys 
A B
Figure 4. Effect of phenylephrine (PE) on membrane potential measured in mesenteric vessels isolated from wild-type (WT) and PLM3SA (3SA) mice.
A, Effect of ouabain (300 µmole/L) on basal membrane potential measured in WT and PLM3SA mesentery. Resting membrane potential was more hyperpolarized in 
WT than PLM3SA vessels—an effect that was lost when vessels were exposed to ouabain. Comparisons were made using 1-way ANOVA followed by an unpaired 
t test (*P<0.05). B, PE induces an equivalent dose-dependent net depolarization in both PLM3SA and WT vessels with the WT vessels starting approximately 5 mV 
more hyperpolarized. Comparisons were made using 2-way ANOVA with Bonferroni correction and #P<0.0001 for effect of both genotype and PE concentration 
and specifically *P<0.05 (n=4 [WT] and n=6 [3SA]). PLM3SA indicates phospholemman (FXYD1) in which the 3 phosphorylation sites on serines 63, 68, and 69 are 
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the proposed endoplasmic reticulum retention motif in 
phospholemman.40 In human embryonic kidney cells, 
the R70C phospholemman mutation is not phosphory-
lated at Ser68 by PKC (Figure 6B and 6C), and displays 
enhanced cell surface localization and palmitoylation 
(Figure XII in the Data Supplement), whereas phosphor-
ylation at the more remote Ser63 site by PKC was unaf-
fected by the R70C mutation (Figure 6D).
To assess the impact of this SNP, we analyzed data 
from UKBB including a total of 357 151 unrelated in-
dividuals of European ancestry, with 159 204 men and 
197 947 women (Table I in the Data Supplement). In 
total, 7114 individuals carried at least 1 copy of the 
rare T allele of the SNP rs61753924, with a minor allele 
frequency of 1% and no evidence of departure from 
Hardy-Weinberg equilibrium (P=0.33). At recruitment, 
mean age was 56.4 years, mean systolic BP (SBP) was 
140.5 mm Hg, and mean diastolic BP (DBP) was 84.1 
mm Hg, with 50.2% of individuals being hypertensive 
(SBP≥140 mm Hg or DBP≥90 mm Hg), and 17.2% re-
ported they were taking BP-lowering medication.
Within UKBB, this SNP is associated with BP in a sex- 
and age-dependent manner (Figure 7). The rare T allele is 
significantly associated with increasing levels of both SBP 
(0.77 mm Hg [95% CI, 0.14–1.4]; P=0.017) and DBP (0.4 
mm Hg [95% CI, 0.02–0.79]; P=0.04) in men. However, 
there is no significant association with BP in either the 
overall sample (P=0.16 for SBP; P=0.11 for DBP) or within 
women (P=0.85 for SBP; P=0.75 for DBP). This suggests a 
sex-specific association. Focusing on results within men, 
Figure 7A illustrates an age-dependent effect of this SNP, 
with the association significant only in the age-stratified 
analyses for men 45 to 50 years and 50 to 55 years old. In-
deed, an initial age-stratified analysis comparing men ≤55 
years old versus men >55 years old shows that the rare 
T allele is significantly associated with increasing levels of 
both SBP (1.2 mm Hg [95% CI, 0.30–2.11]; P=8.89×10–3) 
and DBP (0.79 mm Hg [95% CI, 0.18–1.4]; P=0.01) in 
men <55 years old, but is not significantly associated with 
BP in men >55 years old (P=0.28 for SBP; P=0.48 for DBP). 
We therefore conclude that the SNP has strongest effect 
in middle-aged men, with the rare T allele significantly 
increasing both SBP (1.7 mm Hg [95% CI, 0.59–2.8]; 
P=2.62×10–3) and DBP (1.02 mm Hg [95% CI, 0.29–1.74]; 
P=5.96×10–3) in men 45 to 55 years of age (Figure 7E).
In a similar analysis in the GoDARTS cohort (n=7784), 
the proportion of individuals carrying the T allele was 
slightly higher at 3% compared with UKBB, although 
A B C
D E F
Figure 5. Aging-induced essential hypertension was associated with significant PLM hypo-phosphorylation in wild-type mice.
PLM3SA mice were substantially protected against both this aging-induced hypertension and the associated cardiac hypertrophy and contractile dysfunction. A, 
Aging-induced essential hypertension measured over 48 hours in telemetered young (14–16 weeks) and old (57–60 weeks) wild-type (WT) mice. B, In PLM3SA 
mice, the diurnal fluctuation of BP was similar to that in young WT mice, but nocturnal hypertension was significantly attenuated in PLM3SA mice. C, Average mean 
arterial pressures (MAPs) recorded in young and old mice during day and night by genotype. D and E, In WT mice, PLM was substantially hypophosphorylated at 
Ser63, Ser68, and Ser69 in aortic tissue from old mice (n=6 per group, *P<0.05). F, PLM3SA mice were also protected against aging-induced cardiac contractile 
dysfunction (ejection fraction; see also Figure XI in the Data Supplement). A and B, Comparisons were made using 2-way ANOVA with Bonferroni correction and 
#P<0.001 for effect of both age and time and specifically *P<0.05. C and F, Comparisons were made using 1-way ANOVA with Bonferroni correction. E, Unpaired 
t test was used for comparison. n=10 (adult, WT), n=9 (old, WT), n=11 (adult, PLM3SA), n=11 (old, PLM3SA), *P<0.05, **P<0.01, ***P<0.001. 3SA indicates 
PLM3SA; PLM, phospholemman; and PLM3SA, phospholemman (FXYD1) in which the 3 phosphorylation sites on serines 63, 68, and 69 are mutated to alanines. 
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in Hardy-Weinberg equilibrium (P=0.7). We replicated 
the findings from UKBB with the T allele showing sig-
nificant association with SBP increased by 4.5 mm Hg 
(95% CI, 0.72 to 8.27; P=0.02) only in middle-aged 
men 40 to 65 years.
DISCUSSION
These studies demonstrate the importance of phospho-
lemman-mediated regulation of vascular smooth muscle 
Na/K ATPase activity, membrane potential, tone, and 
BP. Phospholemman phosphorylation stimulates Na/K 
ATPase, which limits agonist-induced vascular smooth 
muscle depolarization and hence limits constriction (Fig-
ure 8). The presence of an SNP that abolishes phospho-
lemman phosphorylation at Ser68 by PKC is significantly 
associated with increased BP in middle-aged men. Muta-
tion of the phosphoregulatory sites on phospholemman 
in mice blocks this pathway and renders vascular smooth 
muscle hyperresponsive to phenylephrine. These PLM3SA 
mice show a chronic adaptation of their baroreceptor sen-
sitivity, which can maintain normal BP at rest in response 
to exogenous phenylephrine (or environmental stress) de-
spite a profoundly enhanced peripheral vasoconstriction. 
The autonomic adaptations in these mice can prevent 
chronic essential hypertension induced by aging. In aged 
WT mice, the combination of increased phospholemman 
expression and profound phospholemman hypophos-
phorylation is associated with hypertension, which was 
largely abrogated by autonomic adaptations in PLM3SA 
mice. This raises the possibility that phospholemman and 
the prevention of its dephosphorylation and Na/K ATPase 
inhibition may provide a novel therapeutic target in ag-
ing-induced essential hypertension.
Mechanism of Phospholemman-Mediated 
Modulation of Vasoconstriction
Many studies have shown that Na/K ATPase modulates 
vascular tone independent of changes in intracellular 
A B
C D
Figure 6. The R70C mutation limits protein kinase C (PKC) but not protein kinase A (PKA) phosphorylation of phospholemman (PLM) at Ser68 but 
does not affect phosphorylation at the more remote Ser63.
A, Position of the R70C mutation in human PLM. The PKC and PKA phosphorylation sites at Ser63, Ser68, and T69 are indicated. B, Phosphospecific immunoblots 
after activation of PKA or PKC in transfected wild-type (WT) and R70C human embryonic kidney cells. C and D, Quantified PLM Ser68 and Ser63 phosphorylation, 
respectively. Unpaired t test was used for comparison (C, n=7 per group and D, n=3–5 per group). *P<0.05; **P<0.005. All other comparisons between WT and 
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Na.3,41,42 We therefore propose that activation of vascu-
lar smooth muscle Na/K ATPase, and the phospholem-
man-mediated ouabain-sensitive relaxing effect, involve 
increased electrogenic Na/K pump current, which hyper-
polarizes the cell membrane or limits agonist-induced de-






Figure 7. The R70C phospholemman mutation (rs61753924) is associated with an age- and sex-dependent effect on BP in 2 human cohorts—UK 
Biobank (UKBB) and GoDARTS.
CC is the comparator (control), and CT and TT represent heterozygote and homozygote genotypes. Mean systolic and diastolic blood pressures (BPs), within 
5-year age intervals, are shown in both cohorts. The T-allele was associated with a significant increase in both systolic and diastolic BP in men (A and B) but not 
women (C and D), and was especially associated within middle-aged men (E and F). A through D, Plot of the mean BP estimates within each age group and 
tests for significant differences between consecutive age groups, according to nonoverlapping 95% CIs. E and F, Mean BP estimates within middle-aged subjects 
corresponding to results from the age-stratified linear regression analyses, testing for a significant difference in mean BP between CC vs CT/TT genotype groups. 
Sample sizes: UKBB, n=159 204 men (A), 197 947 women (C), 44 995 middle-aged (45–55 y) men, and 58 194 middle-aged women (E). GoDARTS: n=4460 men 
(B), 3324 women (D), 1786 middle-aged (45–60 y) men, and 1187 middle-aged women (F). *P<0.05. GoDARTS indicates Genetics of Diabetes Audit and Research 
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in PLM3SA mice profoundly depolarizes resting membrane 
potential in mesenteric arteries from –55±2 mV (WT) to 
–50±1 mV (PLM3SA). The steep current-voltage relationship 
of the L-type Ca channel window current means that such 
a change in membrane potential can significantly increase 
steady-state Ca influx and hence increase vascular tone 
in PLM3SA vessels. In WT vessels, this ouabain-sensitive 5 
mV hyperpolarization persisted across the entire range 
of depolarizations induced by phenylephrine. In these 
mesenteric vessels, this hyperpolarization was not further 
enhanced by a concentration-dependent phenylephrine-
induced Na/K pump activation, because phospholemman 
phosphorylation was not further increased by phenyleph-
rine treatment (unlike in aorta).
Differences in the Role of 
Phospholemman in U46619 and 
Phenylephrine-Induced Constriction
Our data suggest that the constrictive effects of phen-
ylephrine are limited by 2 factors: (1) phospholemman 
phosphorylation activating the Na/K ATPase and (2) 
endothelially derived NO release. Neither of these 
occurs in U46619 constriction because the Na/K 
ATPase is already inhibited by U46619, and U46619 
has been reported to inhibit rather than promote NO 
release from the endothelium.43,44
Role of NO in Phospholemman 
Modulation of Relaxation
Figure IV in the Data Supplement also shows that NO, as in 
cardiac muscle,38 can also induce phospholemman phos-
phorylation. Hence, a component of classical NO-mediated 
relaxation is likely to involve the activation of Na/K ATPase 
via this mechanism. Because phenylephrine also stimulates 
the generation of NO,37 it can therefore limit constriction 
through direct PKC-mediated phosphorylation of phospho-
lemman and also via more classical NO-dependent down-
stream pathways that are phospholemman-independent.
NOS inhibition significantly augmented dose-depen-
dent constriction to phenylephrine in both genotypes 
Figure 8. Proposed mechanisms by which phospholemman (PLM) phosphorylation and Na/K ATPase activation modulate vascular contractility.
1, Activation of cell surface receptors (ie, by phenylephrine or noradrenaline [NA]) activates IP3 and protein kinase C (PKC). 2, This elevates cytosolic Ca through a 
combination of membrane depolarization and enhanced Ca entry (principally via voltage-gated channels) and cyclic sarcoplasmic reticulum (SR) Ca release leading 
to constriction. 3, PKC, whose activation is enhanced by elevation of cytosolic Ca, phosphorylates phospholemman (at either Ser63 or both Ser63 and Ser68). 4, 
Phosphorylated PLM disinhibits the Na/K ATPase (NKA), which generates an outward current limiting the depolarization of the cell membrane and hence limiting 
Ca influx through voltage-gated channels and/or lowers cytoplasmic Na facilitating Ca efflux via Na/Ca exchange. This limits the rise in Ca in the cytosol and hence 
limits constriction. 5, The receptor-mediated rise in cytosolic Ca also passes to adjacent endothelial cells, where it activates both nitric oxide synthase (NOS) and the 
release of endothelium-derived hyperpolarizing factor (EDHF). Nitric oxide (NO) diffuses to smooth muscle cells, where it limits constriction by 2 pathways: (i) via 
the canonical cGMP/protein kinase G (PKG) pathway (6) and (ii) via activation of a PLM/NKA-dependent pathway (7). EDHF release from endothelial cells may also 
limit depolarization, possibly via activation of ouabain-sensitive NKA. 8, Basal phosphorylation of PLM influences vascular tone via these mechanisms and, in the 
PLM3SA mouse, adaptive changes in baroreceptor reflex gain and autonomic control maintain baseline resting blood pressure despite enhanced vascular reactivity 
(9). In aged mice, and in humans expressing the R70C mutation, defects in this PLM/NKA mechanism contribute to hypertension. PLM3SA indicates phospholem-
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(Figure III in the Data Supplement), demonstrating the 
presence of a phospholemman-independent effect of 
phenylephrine that antagonizes constriction. However, 
potentiation of constriction by L-NAME was most pro-
found in the WT aortic segments (Figure III in the Data 
Supplement), suggesting that phospholemman phos-
phorylation plays a role in NO-dependent modulation 
of phenylephrine-induced constriction. Interestingly, 
even in the presence of L-NAME, aortic constriction to 
phenylephrine was higher in PLM3SA mice than in WT 
(Figure III in the Data Supplement), demonstrating that 
phenylephrine activates a complex array of NO-depen-
dent/independent and phospholemman-dependent/
independent mechanisms that antagonize phenyleph-
rine-induced constriction.
The assumption is that the PLM3SA mutation  in PLM 
mediates its effects by influencing Na/K ATPase activity in 
vascular smooth muscle. However, the PLM3SA is a global 
knock-in under the control of the endogenous phospho-
lemman promotor. However, FXYD proteins are ubiqui-
tous, and it is likely that vascular endothelium will express 
its own FXYD protein, which has yet to be identified. 
It seems unlikely that this will be FXYD1 (phospholem-
man), as all reports suggest that this is muscle-specific. 
We have failed to detect phospholemman in endothe-
lial cell cultures (human umbilical vein endothelial cells) 
(data not shown). None of the other members of the 
FXYD family contain the cytoplasmic tail with the regu-
latory phosphorylation site, so they could not be candi-
dates for modulation by phosphorylation. Should aortic 
vascular endothelium express FXYD1 (phospholemman), 
this could affect the Na gradient in endothelial cells and 
hence intracellular Ca and NOS-induced NO release.
In Vivo Adaptations and Control of BP
The role of phospholemman phosphorylation in the 
regulation of vascular tone was also confirmed in vivo. 
AI is influenced by the velocity and amplitude of the 
aortic pressure wave reflection and is proportional to 
arterial stiffness.45–48 In PLM3SA mice, AI was similar to 
that in WT at baseline, but the response to acute ad-
ministration of phenylephrine was profoundly ampli-
fied in PLM3SA mice (Figure 2A). In addition, hind-limb 
resistance vessels also show enhanced constriction in 
response to bolus infusion of phenylephrine in PLM3SA 
mice (Figure 2B–2D).
Surprising, despite this profoundly enhanced vas-
cular responsiveness, in vivo BP was not different 
between the genotypes even during phenylephrine 
infusion (Figure  3A). This lack of enhanced pressor 
response to phenylephrine despite a profound in-
crease in both central and peripheral vasoconstric-
tion is explained by an enhanced reflex bradycardia 
(Figure 3B). This is best demonstrated by the change 
in baroreflex gain in Figure  3C. The PLM3SA mouse 
has a baroreflex sensitivity almost 3 times that of the 
WT mouse (1.42±0.11 versus 0.5±0.07 ms·mm Hg–1). 
There also appears to be an autonomic compensa-
tion under baseline conditions that is reflected in 
reduced the low/high frequency ratio (sympathetic 
dominance) of heart rate variability (Figure 3D) mea-
sured in conscious telemetered mice. Pharmacologi-
cal inhibition of sympathetic and parasympathetic 
activity revealed substantially lower activity in both 
limbs of the autonomic nervous system and lower 
intrinsic heart rate in PLM3SA mice (Figure VID in the 
Data Supplement). New environment stress induced 
similar elevation of BP in both genotypes, but again, 
the chronotropic response was limited in PLM3SA 
mice (Figure VIB and VIC in the Data Supplement). 
Thus, different autonomic control of heart rate, low-
er intrinsic pacemaker activity, and higher baroreflex 
sensitivity appear to underlie adaptive mechanisms 
allowing PLM3SA mice to maintain normal arterial BP 
despite the absence of phospholemman-dependent 
modulation of vascular function.
Phospholemman Phosphorylation and 
Aging-Induced Essential Hypertension
Aging in WT mice is associated with essential hyperten-
sion (Figure 5A and 5C) and a gradual increase in arterial 
stiffness.49 There is a profound age-related reduction of 
phospholemman phosphorylation at all phospholem-
man phosphorylation sites accompanied by increased 
phospholemman expression in aortic tissue (Figure 5D 
and 5E). This combination of increased phospholem-
man expression and profound dephosphorylation will 
inhibit Na/K ATPase. A reduction in Na/K ATPase activity 
may not only affect vascular tone, as described in this 
study, but also lead to chronic vascular remodeling.7 
PLM3SA mice were significantly protected against this 
aging-induced hypertension, and heart rate variability 
analysis suggests that these old PLM3SA mice maintain 
their adaptive changes in autonomic function in a way 
that protects them against aging-induced hypertension 
(Figure X in the Data Supplement).
Our previous studies demonstrated that PLM3SA mice 
are more prone to cardiac hypertrophy and dysfunction 
in a banding model of heart failure.29 However, it is in-
teresting to note that aged PLM3SA mice in this study 
show no cardiac hypertrophy and reduced contractile 
dysfunction compared with aged WT littermates (Fig-
ure 5F, Figure XI in the Data Supplement). This suggests 
that the reduction in the trigger for hypertrophy (ie, 
essential hypertension) in aging PLM3SA mice can com-
pensate for the previously shown vulnerability of these 
mice to pressure overload.
Although it is tempting to suggest that the down-
regulation of Na/K pump function in WT mice is caus-
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the protection afforded in the PLM3SA mouse suggests 
a causal role for phospholemman phosphorylation, it is 
also possible that the chronic downregulation of sympa-
thetic outflow in the PLM3SA mouse is akin to a lifetime 
of β-blockade, and the changes in WT phospholemman 
are merely coincidental.
Therapeutic Potential of Targeting the 
Phospholemman/NKA Regulatory Axis in 
Hypertension
In humans, the R70C phospholemman mutation 
(rs61753924) has a significant impact on BP profiles. At 
middle age, possession of the T allele is associated with 
both increased SBP and DBP levels. In particular, middle-
aged male carriers have 1.7 mm Hg higher mean SBP. 
Within the general population, an effect of this size for 
a single SNP alone is substantial. The results of BP ge-
netic association studies, considering the effect of all 
common variants (minor allele frequency≥1%) associ-
ated with BP, show that the maximum effect size for a 
single common variant is ≈1.2 mm Hg for SBP, with the 
average effect size across all SBP-associated SNPs being 
≈0.3 mm Hg.50 Furthermore, even the genetic risk score 
combining the effects of all 901 independent BP-asso-
ciated SNPs reported in 2018 shows an aggregated risk 
of only ≈10 mm Hg difference in mean SBP when com-
paring individuals in the top versus bottom 20% of the 
genetic risk distribution. Of course, there is an increas-
ing trend between the effect size of associated SNPs 
and their minor allele frequency, with only rare variants 
expected to have larger effects, and indeed, this is a 
low-frequency SNP with minor allele frequency=1%; 
however, even in recent BP genetic studies investigat-
ing rare variants, few individual SNPs have still been 
identified with an effect size for SBP of >2 mm Hg.51 
We note, however, that because of the rare frequency 
of this SNP, and considering the highly polygenic nature 
of BP within the general human population, we do not 
claim any strong clinical impact for this SNP alone. In-
stead, it is only really genetic mutations for monogenic 
hypertension syndromes that are expected to have larg-
er, clinically meaningful effect sizes for single mutation 
variants.50,51 Therefore, we suggest that the large effect 
size of this SNP for increasing BP levels within middle-
aged men demonstrates the importance of the phos-
pholemman/Na/K ATPase regulatory pathway in the 
overall control of BP. Phospholemman-mediated Na/K 
ATPase activation may offer therapeutic potential for 
poorly managed essential hypertension.
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